Skip to main content

Kewalramani Reshma's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Dec 19, 2023

Accession no.
0000875320-23-000062
Filed
Dec 19, 2023
Trade date
Dec 15, 2023
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.97M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kewalramani ReshmaCIK 0001735944Director, Officer (CEO & President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2023Common StockMOption exerciseAcquired+3,058$155.57+$475,733.06111,769Direct
Dec 15, 2023Common StockMOption exerciseAcquired+14,077$187.53+$2,639,859.81125,846Direct
Dec 15, 2023Common StockSSaleDisposed−17,135$407.00−$6,973,945108,711Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 15, 2023Common StockMOption exerciseDisposed−3,058$0.00$00Direct
Dec 15, 2023Common StockMOption exerciseDisposed−14,077$0.00$01,565Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)